IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v38y2020i8d10.1007_s40273-020-00906-6.html
   My bibliography  Save this article

Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model

Author

Listed:
  • Jason Gordon

    (Health Economics and Outcomes Research Limited)

  • Oliver Darlington

    (Health Economics and Outcomes Research Limited)

  • Phil McEwan

    (Health Economics and Outcomes Research Limited)

  • Matthew Lumley

    (Pfizer)

  • Amer Taie

    (Pfizer)

  • Meagen Hicks

    (Pfizer)

  • Claudie Charbonneau

    (Pfizer)

  • Angela Blake

    (Pfizer)

  • Neil Hawkins

    (University of Glasgow)

  • Simon Goldenberg

    (Guy’s and St Thomas’ NHS Foundation Trust)

  • Jonathan Otter

    (Imperial College London)

  • Mark Wilcox

    (University of Leeds)

Abstract

Objectives Antimicrobial resistance (AMR) represents a significant threat to patient and population health. The study aim was to develop and validate a model of AMR that defines and quantifies the value of new antibiotics. Methods A dynamic disease transmission and cost-effectiveness model of AMR consisting of three components (disease transmission, treatment pathway and optimisation) was developed to evaluate the health economic value of new antibiotics. The model is based on the relationship between AMR, antimicrobial availability and consumption. Model analysis explored the impact of different antibiotic treatment strategies on the development of AMR, patient and population estimates of health benefit, across three common treatment indications and pathogens in the UK. Results Population-level resistance to existing antimicrobials was estimated to increase from 10.3 to 16.1% over 10 years based on current antibiotic availability and consumption. In comparison, the diversified use of a new antibiotic was associated with significant reduction in AMR (12.8% vs. 16.1%) and quality-adjusted life year (QALY) gains at a patient (7.7–10.3, dependent on antimicrobial efficacy) and population level (3657–8197, dependent on antimicrobial efficacy and the prevalence of AMR). Validation across several real-world data sources showed that the model output does not tend to systematically under- or over-estimate observed data. Conclusions The development of new antibiotics and the appropriate use of existing antibiotics are key to addressing the threat of AMR. This study presents a validated model that quantifies the value of new antibiotics through clinical and economic outcomes of relevance, and accounts for disease transmission of infection and development of AMR. In this context, the model may be a useful tool that could contribute to the decision-making process alongside other potential models and expert advice.

Suggested Citation

  • Jason Gordon & Oliver Darlington & Phil McEwan & Matthew Lumley & Amer Taie & Meagen Hicks & Claudie Charbonneau & Angela Blake & Neil Hawkins & Simon Goldenberg & Jonathan Otter & Mark Wilcox, 2020. "Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model," PharmacoEconomics, Springer, vol. 38(8), pages 857-869, August.
    • Handle: RePEc:spr:pharme:v:38:y:2020:i:8:d:10.1007_s40273-020-00906-6
    DOI: 10.1007/s40273-020-00906-6
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-020-00906-6
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-020-00906-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Karlsberg Schaffer, S. & West, P. & Towse, A. & Henshall, C. & Mestre-Ferrandiz, J. & Masterson, R. & Fischer, A., 2017. "Additional Elements of Value for Health Technology Assessment Decisions," Briefings 001851, Office of Health Economics.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.
    2. Colm Leonard & Nick Crabb & David Glover & Sophie Cooper & Jacoline Bouvy & Milena Wobbe & Mark Perkins, 2023. "Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?," Applied Health Economics and Health Policy, Springer, vol. 21(3), pages 365-372, May.
    3. Sofie Larsson & Charlotta Edlund & Pontus Nauclér & Mikael Svensson & Anders Ternhag, 2022. "Cost-Effectiveness Analysis of Temocillin Treatment in Patients with Febrile UTI Accounting for the Emergence of Antibiotic Resistance," Applied Health Economics and Health Policy, Springer, vol. 20(6), pages 835-843, November.
    4. Margherita Neri;Adrian Towse, 2017. "Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?," Briefing 001922, Office of Health Economics.
    5. Brassel, Simon & Al Taie, Amer & Steuten, Lotte, 2023. "Value assessment of antimicrobials using the STEDI framework – How steady is the outcome?," Health Policy, Elsevier, vol. 136(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:38:y:2020:i:8:d:10.1007_s40273-020-00906-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.